CoChat

Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials

Open access

The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.

Abstract

Background Elevated lipoprotein(a) is a genetic risk factor for cardiovascular disease in general population studies. However, its contribution to risk for cardiovascular events in patients with established cardiovascular disease or on statin therapy is uncertain.Methods Patient-level data from seven randomised, placebo-controlled, statin outcomes trials were collated and harmonised to calculate hazard ratios (HRs) for cardiovascular events, defined as fatal or non-fatal coronary heart disease, stroke, or revascularisation procedures. HRs for cardiovascular events were estimated within each trial across predefined lipoprotein(a) groups (15 to <30 mg/dL, 30 to <50 mg/dL, and ≥50 mg/dL, vs <15 mg/dL), before pooling estimates using multivariate random-effects meta-analysis.Findings Analyses included data for 29 069 patients with repeat lipoprotein(a) measurements (mean age 62 years [SD 8]; 8064 [28%] women; 5751 events during 95 576 person-years at risk). Initiation of statin therapy reduced LDL cholesterol (mean change -39% [95% CI -43 to -35]) without a significant change in lipoprotein(a). Associations of baseline and on-statin treatment lipoprotein(a) with cardiovascular disease risk were approximately linear, with increased risk at lipoprotein(a) values of 30 mg/dL or greater for baseline lipoprotein(a) and 50 mg/dL or greater for on-statin lipoprotein(a). For baseline lipoprotein(a), HRs adjusted for age and sex (vs <15 mg/dL) were 1·04 (95% CI 0·91-1·18) for 15 mg/dL to less than 30 mg/dL, 1·11 (1·00-1·22) for 30 mg/dL to less than 50 mg/dL, and 1·31 (1·08-1·58) for 50 mg/dL or higher; respective HRs for on-statin lipoprotein(a) were 0·94 (0·81-1·10), 1·06 (0·94-1·21), and 1·43 (1·15-1·76). HRs were almost identical after further adjustment for previous cardiovascular disease, diabetes, smoking, systolic blood pressure, LDL cholesterol, and HDL cholesterol. The association of on-statin lipoprotein(a) with cardiovascular disease risk was stronger than for on-placebo lipoprotein(a) (interaction p=0·010) and was more pronounced at younger ages (interaction p=0·008) without effect-modification by any other patient-level or study-level characteristics.Interpretation In this individual-patient data meta-analysis of statin-treated patients, elevated baseline and on-statin lipoprotein(a) showed an independent approximately linear relation with cardiovascular disease risk. This study provides a rationale for testing the lipoprotein(a) lowering hypothesis in cardiovascular disease outcomes trials.Funding Novartis Pharma AG.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(18)31652-0

Cites

41 of 41 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

The text we found for this paper looks like another document, so its claims and self-check weren’t run. The registry and citation checks still apply.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The text we found for this paper looks like another document, so the self-check wasn’t run.

Citations

Cites

Show all 41 references

Research works printed but not linked: 1

  1. O'Donoghue, 2014, Lipoprotein(a) for risk assessment in patients with established coronary artery disease, J Am Coll Cardiol, 63, 520, 10.1016/j.jacc.2013.09.042 · DOI · Paper page

Cited by

See all 594

Metadata

Authors
Willeit, P., Ridker, P. M., Nestel, P. J., Simes, J., Tonkin, A. M., Pedersen, T. R., Schwartz, G. G., Olsson, A. G., Colhoun, H. M., Kronenberg, F., Drechsler, C., Wanner, C., Mora, S., Lesogor, A., & Tsimikas, S.
Affiliations
  • Innsbruck Medical University (AT)
  • Brigham and Women's Hospital (US)
  • Baker Heart and Diabetes Institute (AU)
  • The University of Sydney (AU)
  • Monash University (AU)
  • Oslo University Hospital (NO)
  • Denver VA Medical Center (US)
  • Linköping University (SE)
  • Institute of Genetics and Cancer (GB)
  • Universitätsklinikum Würzburg (DE)
  • Novartis (Switzerland) (CH)
  • UC San Diego Health System (US)
Corresponding author
  • Willeit, Peter
  • Tsimikas, Sotirios
Venue
The Lancet
Publisher
Elsevier BV
Published
2018-10
Volume
392
Issue
10155
Pages
1311-1320
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2894645224
Cited by
564
References
41
Citations by year
2026: 52 · 2025: 64 · 2024: 79 · 2023: 73 · 2022: 79 · 2021: 62 · 2020: 72 · 2019: 76 · 2018: 7
FWCI
12.07
Type
journal article
Language
en
Open access
Licence
  • other-oa
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Edinburgh Research Explorer (University of Edinburgh) (publishedVersion, other-oa)
Funders
  • National Institutes of Health (R01 HL117861, R01 HL134811, K24 HL136852)
  • NIH (R01-HL119828, R01-HL078610, R01 HL106579, R01 HL128550, R01 HL136098, P01 HL136275, R35 HL135737)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
lipoprotein(a), statin therapy, cardiovascular risk prediction, cardiovascular events, LDL cholesterol, coronary artery disease, stroke, revascularization, genetic risk factors, individual patient data meta-analysis, cardiovascular disease prevention, cardiovascular risk stratification
MeSH terms
Aged, Cardiovascular Diseases, Female, Humans, Hypercholesterolemia, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Risk Factors, Biomarkers, Randomized Controlled Trials as Topic, Lipoprotein(a), Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. https://app.cochat.ai/papers/10.1016/s0140-6736(18)31652-0
The paper
Willeit, P., Ridker, P. M., Nestel, P. J., Simes, J., Tonkin, A. M., Pedersen, T. R., Schwartz, G. G., Olsson, A. G., Colhoun, H. M., Kronenberg, F., Drechsler, C., Wanner, C., Mora, S., Lesogor, A., & Tsimikas, S. (2018). Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. The Lancet. https://doi.org/10.1016/s0140-6736(18)31652-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.